Get started
Author

William M. Garrett

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
2015 · Alessandro M. Vannucchi, Jean Jacques Kiladjian, et al. · New England Journal of Medicine · 893
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
2015 · Herbert I. Hurwitz, Nikhil Uppal, et al. · Journal of Clinical Oncology · 292
Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)
2010 · Srdan Verstovsek, Francesco Passamonti, et al. · Blood · 61
A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
2014 · Herbert Hurwitz, Nikhil Uppal, et al. · Journal of Clinical Oncology · 50
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.
2009 · Srdan Verstovsek, Francesco Passamonti, et al. · Blood · 48
Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients.
2009 · S. Friedman, R. Levy, et al. · Cancer Research · 39
Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
2014 · Srdan Verstovsek, Jean-Jacques Kiladjian, et al. · Journal of Clinical Oncology · 16
Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.
2009 · Farhad Ravandi, Srdan Verstovsek, et al. · Blood · 8
JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy.
2015 · Herbert Hurwitz, William M. Garrett, et al. · Journal of Clinical Oncology · 7
RESPONSE: A randomized, open-label, phase III study of ruxolitinib in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
2012 · Srdan Verstovsek, Jean-Jacques Kiladjian, et al. · Journal of Clinical Oncology · 7
Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial
2014 · H. Hurwitz, N. Uppal, et al. · Annals of Oncology · 3
PDF
Works count: 11
Citation count: 1,423
H-index: 8
I10-index: 7
Year
Topic
Type